FDA Warns Harper Meds Over Compounded GLP-1 Labeling, Ozempic Comparisons, and "FDA-Licensed" Facility Claims
On June 8, 2026, FDA issued a warning letter to Harper Meds after a March 2026 review of harpermeds.com, which offers compounded semaglutide and tirzepatide products. FDA cited product labels identifying "Harper Meds" as if it were the compounder "when in fact it is not," claims like "Same active ingredient as Ozempic™ & Wegovy™," and a claim that products are sourced from "FDA-licensed 503A Outsourcing Facilities" — wording FDA calls "false and misleading" since it grants no such designation. FDA requested a written response within 15 business days.
What this meansFDA does not approve or license compounding pharmacies, so "FDA-approved pharmacy" language on a provider's site is worth questioning — how a provider describes its pharmacy partners says a lot about how carefully it operates.
Source: FDA original ↗